Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9NS91

UPID:
RAD18_HUMAN

ALTERNATIVE NAMES:
Postreplication repair protein RAD18; RING finger protein 73; RING-type E3 ubiquitin transferase RAD18

ALTERNATIVE UPACC:
Q9NS91; Q58F55; Q9NRT6

BACKGROUND:
The E3 ubiquitin-protein ligase RAD18, also known as RING finger protein 73 and RING-type E3 ubiquitin transferase RAD18, is integral to the cellular response to DNA damage. By forming a complex with UBE2B, RAD18 facilitates the mono-ubiquitination of PCNA, a crucial step in the postreplication repair pathway. This activity not only underscores the protein's essential role in preserving genomic stability but also its potential as a biomarker for DNA repair efficiency.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of E3 ubiquitin-protein ligase RAD18 offers a pathway to novel therapeutic avenues. Given its central role in repairing UV-damaged DNA, targeting RAD18 could lead to innovative treatments that bolster the DNA repair capacity, particularly beneficial for diseases characterized by impaired DNA repair mechanisms.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.